- Home
- CTRM vs AEON Comparison
CTRM vs AEON Comparison
Compare CTRM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- AEON
- Stock Information
- Founded
- CTRM 2016
- AEON N/A
- Country
- CTRM Cyprus
- AEON United States
- Employees
- CTRM N/A
- AEON N/A
- Industry
- CTRM Marine Transportation
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- AEON Health Care
- Exchange
- CTRM Nasdaq
- AEON Nasdaq
- Market Cap
- CTRM 37.6M
- AEON 36.4M
- IPO Year
- CTRM N/A
- AEON N/A
- Fundamental
- Price
- CTRM $3.57
- AEON $0.54
- Analyst Decision
- CTRM
- AEON Strong Buy
- Analyst Count
- CTRM 0
- AEON 1
- Target Price
- CTRM N/A
- AEON $5.00
- AVG Volume (30 Days)
- CTRM 63.4K
- AEON 111.1K
- Earning Date
- CTRM 11-07-2024
- AEON 11-13-2024
- Dividend Yield
- CTRM N/A
- AEON N/A
- EPS Growth
- CTRM N/A
- AEON N/A
- EPS
- CTRM 2.39
- AEON N/A
- Revenue
- CTRM $76,443,340.00
- AEON N/A
- Revenue This Year
- CTRM N/A
- AEON N/A
- Revenue Next Year
- CTRM N/A
- AEON N/A
- P/E Ratio
- CTRM $1.49
- AEON N/A
- Revenue Growth
- CTRM N/A
- AEON N/A
- 52 Week Low
- CTRM $3.01
- AEON $0.52
- 52 Week High
- CTRM $6.50
- AEON $17.17
- Technical
- Relative Strength Index (RSI)
- CTRM 36.45
- AEON 24.81
- Support Level
- CTRM $3.78
- AEON $0.65
- Resistance Level
- CTRM $4.18
- AEON $0.88
- Average True Range (ATR)
- CTRM 0.15
- AEON 0.07
- MACD
- CTRM -0.02
- AEON -0.02
- Stochastic Oscillator
- CTRM 18.67
- AEON 3.91
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.